2026-09-07

SELECT Trial Explained

SELECT was a randomized, double-blind, placebo-controlled, event-driven trial in adults aged 45 or older with established cardiovascular disease, overweight or obesity, and no history of diabetes. It tested semaglutide against placebo on a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. The trial supports a population-specific cardiovascular finding; it does not turn every semaglutide-labeled or research-market material into the studied product.

The question

The trial asked whether semaglutide added to standard care would reduce major adverse cardiovascular events in a high-risk population without diabetes. The registered study is NCT03574597 on ClinicalTrials.gov. The registry is worth reading because it shows eligibility, design, endpoints, recruitment, sponsor, and study status in one place.

The population is the boundary. Participants had preexisting cardiovascular disease and a BMI of at least 27, were at least 45, and did not have diabetes. Those details are not footnotes; they define what the result can support.

The design and result

The NEJM publication, DOI 10.1056/NEJMoa2307563, reports 17,604 randomized participants and mean follow-up of 39.8 months. The primary composite occurred less often in the semaglutide group than in the placebo group, with a hazard ratio of 0.80 and a 95% confidence interval of 0.72 to 0.90.

That result is often paraphrased as a 20% reduction in relative risk. Keep the wording attached to the endpoint: the composite was cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, analyzed as time to first event. It was not a claim that every participant improved, nor a guarantee about an individual outcome.

The PubMed record provides a stable bibliographic and abstract view. Compare it with the registry and publication rather than relying on a screenshot or social summary.

Product context matters

The trial studied a defined investigational protocol and product supply under trial controls. The DailyMed Wegovy label is a separate record that describes an approved product and its labeling. A research certificate, a compounded product, and an approved product can share a molecule name while differing in formulation, manufacturing, controls, and evidence.

Use the semaglutide overview to keep those layers together without collapsing them. The Explore library and Field Manual offer worksheets for population, endpoint, comparator, and uncertainty.

What SELECT cannot answer

SELECT does not answer every cardiovascular question. It does not establish outcomes for populations excluded from the trial, different formulations, different products, different endpoints, or different follow-up periods. It also does not replace an individual clinical assessment or the current local label.

Limitations

This is trial literacy, not treatment advice. It does not recommend a product or regimen and contains no dosing, injection, reconstitution, administration, vendor, or purchase guidance. Regulatory labels and trial records can change; consult current official sources and a licensed clinician for health decisions.

Sources

• ClinicalTrials.gov: NCT03574597
• NEJM: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
• DOI: 10.1056/NEJMoa2307563
• PubMed: SELECT publication
• DailyMed: Wegovy label